| Goals and targets for personalized therapy for HCC |
39 |
| Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis |
28 |
| Hepatic encephalopathy: a critical current review |
20 |
| Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg |
18 |
| Precision-cut liver slices: a versatile tool to advance liver research |
16 |
| Management of ascites and hepatorenal syndrome |
16 |
| The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting |
15 |
| Budd-Chiari syndrome/hepatic venous outflow tract obstruction |
15 |
| Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis |
14 |
| APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation |
14 |
| Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals |
13 |
| Radiomics in hepatocellular carcinoma: a quantitative review |
13 |
| Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016 |
12 |
| Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium |
11 |
| Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network ActivityLINA cohort) |
10 |
| APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? |
10 |
| New concepts on the clinical course and stratification of compensated and decompensated cirrhosis |
10 |
| Biology of portal hypertension |
9 |
| Pathogenesis of non-alcoholic fatty liver disease mediated by YAP |
9 |
| Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma |
9 |
| DAMPs and sterile inflammation in drug hepatotoxicity |
9 |
| Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges |
9 |
| Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis |
9 |
| Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study |
9 |
| Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka |
9 |
| Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection |
9 |
| Budd-Chiari syndrome has different presentations and disease severity during adolescence |
8 |
| Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype |
8 |
| Chinese guidelines on the management of ascites and its related complications in cirrhosis |
8 |
| Hepatocellular carcinoma and non-alcoholic fatty liver disease |
8 |
| Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis |
8 |
| Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease |
7 |
| Idiopathic portal hypertension and extrahepatic portal venous obstruction |
7 |
| Invasive and non-invasive assessment of portal hypertension |
7 |
| The portal hypertension syndrome: etiology, classification, relevance, and animal models |
7 |
| Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift |
7 |
| Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma |
7 |
| Immune checkpoint receptors: homeostatic regulators of immunity |
7 |
| Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis |
7 |
| A changing paradigm: management and treatment of the HCV/HIV-co-infected patient |
6 |
| Beyond KCH selection and options in acute liver failure |
6 |
| Antifibrotics in liver disease: are we getting closer to clinical use? |
6 |
| Depression, fatigue and neurocognitive deficits in chronic hepatitis C |
6 |
| Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells |
6 |
| Global HBV burden: guesstimates and facts |
6 |
| Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region |
6 |
| Liver damage related to immune checkpoint inhibitors |
6 |
| Immunological cure of HBV infection |
6 |
| Sarcopenia and fatty liver disease |
6 |
| Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome |
5 |
